Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Oct 28, 2023; 29(40): 5557-5565
Published online Oct 28, 2023. doi: 10.3748/wjg.v29.i40.5557
Table 1 Baseline characteristics

ETGF (%)
PCD (%)
P value
Total3438
Male24 (70.6)26 (68.4)0.84
Mean age36.8 ± 12.946.0 ± 16.80.01
Mean length of lesions (mm)109.4 ± 7.894.8 (80.8-133.2)0.89
Cause of pancreastitis
Hyperlipidemia10 (29.4)8 (21.1)
Gallstone8 (23.5)8 (21.1)
Alcohol9 (26.5)6 (15.8)
Trauma1 (2.9)4 (10.5)
Autoimmunity1 (2.9)3 (7.9)
Pancreatic duct stones3 (8.8)
Choledochocyst1 (2.6)
Idiopathic1 (2.9)8 (21.1)
Clinical symptoms1
Abdominal pain (%)24 (70.6)27 (71.1)
Abdominal distention (%)6 (17.65)5 (13.2)
Nausea or vomiting53
Fever61
Asymptomatic12
Preintervention64
PCD43
ETGF1
Surgery11
Opportunity of intervention2        0.381
< 4 wk713    
> 4 wk2124    
Total interventions1.03 ± 0.031.32 ± 0.090.003
Total hospital visits1.0 (0)1.0 (1.0)0.278
Total hospital stays(days)14.5 (10.25)19.0 (20.5)0.177
Total cost ($)4852 (3877)5206 (8377)0.955
Table 2 Endoscopic transgastric fenestration vs percutaneous drainage for management of (peri) pancreatics, n (%)

ETGF
PCD
P value
Technical success34 (100)38 (100)
Clinical success33/34 (97.1)29/38 (76.3)0.01
Recurrence1/34 (2.94)4/38 (10.5)0.42
Reintervention10/34 (29.4)171/38 (44.7)0.18
Complication1.00
Bleeding 4 (11.76)Bleeding 2 (5.26)
Local infection 2 (5.26)
Adhesion to surrounding tissue 1 (2.63)
Catheter related adverse events0.001
    Tube dislodgment 1 (2.9)Intubation time > 8 wk 11 (28.9)
    Drainage obstruction 5 (13.2)